Otsuka (OTCMKTS:OTSKY) Sets New 1-Year High - Still a Buy?

Key Points

• Otsuka's ADR reached a new 52-week high of $36.34 (last $36.29) and was trading up about 3.3% intraday on the report.
• Analyst sentiment is mixed but negative on balance — one Buy, one Hold and two Sell produce an average rating of "Reduce", with Morgan Stanley upgrading to overweight while Goldman Sachs and Zacks moved to strong sell.
• Key fundamentals: market cap roughly $39.25 billion, PE of 15.89, 50-day/200-day moving averages of $32.57/$29.60, and very low leverage (debt-to-equity 0.05), suggesting modest valuation and strong balance-sheet metrics.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $36.34 and last traded at $36.29, with a volume of 1949 shares. The stock had previously closed at $35.37.

Analyst Ratings Changes

A number of analysts have recently weighed in on OTSKY shares. Morgan Stanley raised Otsuka to an "overweight" rating in a research report on Friday, January 23rd. Zacks Research lowered Otsuka from a "hold" rating to a "strong sell" rating in a research report on Monday, March 2nd. The Goldman Sachs Group cut Otsuka from a "strong-buy" rating to a "strong sell" rating in a research note on Friday, February 27th. Finally, UBS Group upgraded shares of Otsuka to a "hold" rating in a research note on Tuesday, January 27th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce".

Otsuka Trading Up 3.3%

The business has a fifty day moving average price of $32.57 and a 200 day moving average price of $29.60. The firm has a market cap of $39.25 billion and a PE ratio of 15.89. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.